DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Oxygenases, 125t
Oxygenation, normal, 555–556
Oxymetazoline, adrenergic receptors
and, 206t
Oxyphenbutazone, 990
Oxytocin
antidiuretic effects of, 1850
for augmentation of dysfunctional
labor, 1850
biosynthesis of, 1124–1125
chemistry, 708–709
clinical use of, 1125–1126
effects of, 1125
for labor induction, 1850
in obstetrics, 1850
opioids and, 495
physiological roles of, 1124–1125
for postpartum hemorrhage,
1850–1851
secretion of, 1125
vasodilating effects of, 1850
Oxytocin receptor antagonists, for
prevention of preterm labor,
1848
P
PA-816, 1561
PABA. See p-Aminobenzoic acid
PACAP. See Pituitary adenylyl cyclaseactivating
peptide (PACAP)
Pacemaker, cardiac, 824t
PACERONE (amiodarone), 834
Package inserts, 9
Paclitaxel, 1668t–1670t
endovascular stents eluting, 772
pharmacokinetics of, 1872t
Pad, prescription, 1881–1882
Padimate O, 1827
Paget’s disease, 1290
extramammary, imiquimod for, 1823
treatment of, 1301
Pain, 961
cancer, 525
drugs for, NSAIDs, 961
eicosanoids and, 951
histamine and, 918
kinins and, 930–931
NSAIDs for, 971
opiates for, 518–522
opioid antagonists and, 513–514
of terminal illness, 525
Paliperidone
dosage of, 425t
metabolism of, 433t
pharmacokinetics of, 1872t
side effects of, 425t
PAMs. See Positive allosteric
modulators (PAMs)
Panaeolus, 225
Pancreas
ABC transporters in, 106t
alpha adrenergic receptors in, 203t
in autonomic nervous system, 179t
ethanol and, 637–638
Pancreatic cancer, 1736
drugs for, 1668t–1670t
Pancreatic enzymes, 1346
Pancreatic islet physiology, 1240–1242
Pancreatic polypeptide, 213
Pancreatitis, 1339
chronic, 1346
Pancuronium
characteristics of, 264t
dosing of, 265t
Panitumumab, 1734, 1745
adverse effects and side effects of,
1737
chemistry, 1737
PANRETIN (alitretinoin), 1811
Pantoprazole
pharmacokinetics of, 1872t
pharmacology of, 1311–1312
therapeutic uses of, for
gastroesophageal reflux
disease, 1318t
Papaverine, 761
PAPS. See 3’-phosphoadenosine-5’-
phosphosulfate (PAPS)
Para-aminophenol derivatives, 982–
984
classification of, 966t
Para-aminosalicylic acid, 1562
Paricalcitol, 1292, 1292f
Paracelsus, 73
Paragonimus westermani, 1449
Paragyline, 200
adrenergic receptors and, 207t
Paraldehyde, 475–476
Paralysis, with succinylcholine, 261
Paralytic ileus, anticholinesterase
agents for, 250
Paraneoplastic pemphigus,
cyclophosphamide for, 1821
Parasites
conjunctivitis caused by, 1782
susceptibility testing in, 1370–1371
Parasympathetic system, 171, 174–175
Parathion, 239, 243
Parathyroid hormone (PTH)
absorption of, 1297
adverse effects of, 1297
bone and, 1279
Parathyroid hormone (PTH) (Cont.):
calcium and, 1278–1280
chemistry of, 1278
clinical uses of, 1297
excretion of, 1297
immunoassay, 1278
kidneys and, 1279
physiological functions of, 1278
regulation of secretion, 1278–1279
secretion of, 1278
synthesis and secretion, 1278
Paravertebral sympathetic ganglia,
173f, 174
Parecoxib, 964–965, 970t, 991–992
adverse effects and side effects of,
991–992
pharmacokinetics of, 991
therapeutic uses of, 991
PAREMYD, for uveitis, 1788
Parenteral administration, 20–22
oral vs., 20
Parkinson disease (PD)
dopamine and, 356–357, 611
drugs for, 614t
amantadine, 614t
levodopa, 614t
selegiline, 614t
muscarinic antagonists and, 234
neural mechanism of, 611–613
neuroprotective treatments for, 619
pathophysiology of, 611
treatment of, 614–619
Parkinsonism, drugs inducing,
neuroleptics, 437t
Paromomycin, 1433–1434
Paroxetine
arrhythmias caused by, 832
disposition of, 409t
pharmacokinetics of, 1873t
polymorphisms and response to, 160t
potencies
at human transporters for monamine
neurotransmitters, 406t
at neurotransmitter receptors, 410t
SLC transporters and, 102t
Paroxysmal supraventricular
tachycardia (PSVT), 822
ECG of, 825f
management of, 824t
Partial epilepsy, 585–588
Particle size, inhaled administration
and, 1034
Partition coefficient
in passive flux across membranes, 18
for percutaneous drug absorption,
1804–1805
2057
INDEX